| Synonym |
| Thai / English name |
Part Used : ใบActivity : PLATELET AGGREGATION INHIBITIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 12N(Treatment) : 12Sex : -Age : 20-36 yrsRoute : Oral administrationDose/Conc.(herb) : 2 tablets x 3 times dailyDuration : 1 week with at least 14-day washoutType of interaction : PharmacodynamicsInteraction with drug : WarfarinDose/Conc.(drug) : -Result : NegativeRemark : The mean ratios of the AUCO-168 of INR were 0.93 (0.82-1.05) following treatment with ginkgo and 1.03 (0.90-1.15) for ginger treatment. These data suggest there is no significant effect of these herbs on warfarin pharmacodynamics. Neither ginkgo nor ginger alone affected baseline INR or ex vivo platelet aggregation in response to arachidonic acid.Note : Each ginger tablet containing 0.4 g of ginger rhizome powder Each Gingko tablet equivalent to 2 g of Ginkgo biloba leaf (9.6 mg of ginkgo flavonglycosides, 2.4 mg of ginkgolides and bilobalide)
Part Used : ใบActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 12N(Treatment) : 12Sex : MaleAge : 20-36 yrsRoute : Oral administrationDose/Conc.(herb) : 2 tablets x 3 times dailyDuration : 1 week with at least 14-day washoutType of interaction : PharmacokineticsInteraction with drug : WarfarinDose/Conc.(drug) : -Result : NegativeRemark : There were no significant changes observed in the pharmacokinetic parameters of S- or R-warfarin in healthy male subjects following treatment with ginkgo or ginger. The urinary excretion rate of S-7-hydroxywarfarin after administration of warfarin alone was no significant difference following treatment with either ginkgo or ginger.Note : Each ginger tablet containing 0.4 g of ginger rhizome powder Each Gingko tablet equivalent to 2 g of Ginkgo biloba leaf (9.6 mg of ginkgo flavonglycosides, 2.4 mg of ginkgolides and bilobalide)
Part Used : ใบActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 12N(Treatment) : 12Sex : MaleAge : 20-36 yrsRoute : Oral administrationDose/Conc.(herb) : 2 tablets x 3 times dailyDuration : 1 week with at least 14-day washoutType of interaction : PharmacokineticsInteraction with drug : WarfarinDose/Conc.(drug) : -Result : NegativeRemark : There were no significant changes observed in the pharmacokinetic parameters of S- or R-warfarin in healthy male subjects following treatment with ginkgo or ginger. The urinary excretion rate of S-7-hydroxywarfarin after administration of warfarin alone was no significant difference following treatment with either ginkgo or ginger.Note : Each ginger tablet containing 0.4 g of ginger rhizome powder Each Gingko tablet equivalent to 2 g of Ginkgo biloba leaf (9.6 mg of ginkgo flavonglycosides, 2.4 mg of ginkgolides and bilobalide)
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 12N(Treatment) : 12Sex : MaleAge : 20-36 yrsRoute : Oral administrationDose/Conc.(herb) : 2 tablets x 3 times dailyDuration : 1 week with at least 14-day washoutType of interaction : PharmacokineticsInteraction with drug : WarfarinDose/Conc.(drug) : -Result : NegativeRemark : There were no significant changes observed in the pharmacokinetic parameters of S- or R-warfarin in healthy male subjects following treatment with ginkgo or ginger. The urinary excretion rate of S-7-hydroxywarfarin after administration of warfarin alone was no significant difference following treatment with either ginkgo or ginger.Note : Each ginger tablet containing 0.4 g of ginger rhizome powder Each Gingko tablet equivalent to 2 g of Ginkgo biloba leaf (9.6 mg of ginkgo flavonglycosides, 2.4 mg of ginkgolides and bilobalide)
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 12N(Treatment) : 12Sex : MaleAge : 20-36 yrsRoute : Oral administrationDose/Conc.(herb) : 2 tablets x 3 times dailyDuration : 1 week with at least 14-day washoutType of interaction : PharmacokineticsInteraction with drug : WarfarinDose/Conc.(drug) : -Result : NegativeRemark : There were no significant changes observed in the pharmacokinetic parameters of S- or R-warfarin in healthy male subjects following treatment with ginkgo or ginger. The urinary excretion rate of S-7-hydroxywarfarin after administration of warfarin alone was no significant difference following treatment with either ginkgo or ginger.Note : Each ginger tablet containing 0.4 g of ginger rhizome powder Each Gingko tablet equivalent to 2 g of Ginkgo biloba leaf (9.6 mg of ginkgo flavonglycosides, 2.4 mg of ginkgolides and bilobalide)
Part Used : ใบActivity : PLATELET AGGREGATION INHIBITIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 12N(Treatment) : 12Sex : MaleAge : 20-36 yrsRoute : Oral administrationDose/Conc.(herb) : 2 tablets x 3 times dailyDuration : 1 week with at least 14-day washoutType of interaction : PharmacodynamicsInteraction with drug : WarfarinDose/Conc.(drug) : -Result : NegativeRemark : There were no significant changes observed in the pharmacokinetic parameters of S- or R-warfarin in healthy male subjects following treatment with ginkgo or ginger. The urinary excretion rate of S-7-hydroxywarfarin after administration of warfarin alone was no significant difference following treatment with either ginkgo or ginger.Note : Each ginger tablet containing 0.4 g of ginger rhizome powder Each Gingko tablet equivalent to 2 g of Ginkgo biloba leaf (9.6 mg of ginkgo flavonglycosides, 2.4 mg of ginkgolides and bilobalide)
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 24N(Treatment) : 24Sex : MaleAge : 26 +/- 5 yearsRoute : Oral administrationDose/Conc.(herb) : -Duration : -Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : WarfarinDose/Conc.(drug) : 25 mgResult : NegativeRemark : Coadministration with either ginkgo or ginger with warfarin did not affect the pharmacokinetics or pharmacodynamics of S-warfarin.Note : Type of clinical study: randomized, open-label, controlled, 3-treatment, and 3-sequence crossover studies with at least a 14-day washout period between study periods of dosing. Subjects: healthy male subjects received a single 25 mg dose warfarin with or without pretreatment with Commission E19 recommended daily doses of St John's wort, Asian ginseng (Panax ginseng), ginkgo (Ginkgo biloba), or ginger from commercially available products of known quality.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 24N(Treatment) : 24Sex : MaleAge : 26 +/- 5 yearsRoute : Oral administrationDose/Conc.(herb) : -Duration : -Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : WarfarinDose/Conc.(drug) : 25 mgResult : NegativeRemark : Coadministration with either ginkgo or ginger with warfarin did not affect the pharmacokinetics or pharmacodynamics of S-warfarin.Note : Type of clinical study: randomized, open-label, controlled, 3-treatment, and 3-sequence crossover studies with at least a 14-day washout period between study periods of dosing. Subjects: healthy male subjects received a single 25 mg dose warfarin with or without pretreatment with Commission E19 recommended daily doses of St John's wort, Asian ginseng (Panax ginseng), ginkgo (Ginkgo biloba), or ginger from commercially available products of known quality.
Part Used : ไม่ระบุActivity : PHARMACOKINETIC STUDY OFSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 24N(Treatment) : 24Sex : MaleAge : 26 +/- 5 yearsRoute : Oral administrationDose/Conc.(herb) : -Duration : -Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : WarfarinDose/Conc.(drug) : 25 mgResult : NegativeRemark : Coadministration with either ginkgo or ginger with warfarin did not affect the pharmacokinetics or pharmacodynamics of S-warfarin.Note : Type of clinical study: randomized, open-label, controlled, 3-treatment, and 3-sequence crossover studies with at least a 14-day washout period between study periods of dosing. Subjects: healthy male subjects received a single 25 mg dose warfarin with or without pretreatment with Commission E19 recommended daily doses of St John's wort, Asian ginseng (Panax ginseng), ginkgo (Ginkgo biloba), or ginger from commercially available products of known quality.
Part Used : ไม่ระบุActivity : PHARMACOKINETIC STUDY OFSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 24N(Treatment) : 24Sex : MaleAge : 26 +/- 5 yearsRoute : Oral administrationDose/Conc.(herb) : -Duration : -Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : WarfarinDose/Conc.(drug) : 25 mgResult : NegativeRemark : Coadministration with either ginkgo or ginger with warfarin did not affect the pharmacokinetics or pharmacodynamics of S-warfarin.Note : Type of clinical study: randomized, open-label, controlled, 3-treatment, and 3-sequence crossover studies with at least a 14-day washout period between study periods of dosing. Subjects: healthy male subjects received a single 25 mg dose warfarin with or without pretreatment with Commission E19 recommended daily doses of St John's wort, Asian ginseng (Panax ginseng), ginkgo (Ginkgo biloba), or ginger from commercially available products of known quality.
